Precision Medicine is a medical approach that proposes to prevent and treat disease based upon a persons unique genetic makeup and their lifestyle habits. Precision medicine, the ability to accurately measure specific predictors of patient outcomes is implemented in personalized clinical care. Doctors have been performing precision medicine and personalized care for many years. For example, high blood pressure (hypertension) is commonly measured as a modifiable risk factor for vascular disease. However, advances in the basic knowledge of biology and disease, and advances in technologies now allow many more biomarkers to be measured to predict disease and target therapy. For example, in breast cancer the precision medicine involves the measurement of estrogen receptor as a biomarker for personalized use of anti-hormone therapy. Precision medicine incorporates the complexity of biology and disease though multi-scale analysis and systems biology. Such analysis often requires large scale data ...
US-based Syapse has formed a strategic alliance with Roche to accelerate product development and clinical delivery for offering precision medicine to more cancer patients and their healthcare providers.. As part of the multi-year collaboration, the firms will work towards the development of software products and analytics solutions to provide tools and insights required to practice precision medicine for enhancing outcomes and quality of life for patients.. The development will be sponsored by Roche, while Syapse will use its platform to develop and deploy the new products to the precision medicine ecosystem.. Syapse CEO Ken Tarkoff said: "Precision medicine is already improving cancer care, and Syapse is empowering healthcare providers with the tools they need to deliver the best possible care.. "By working together, Syapse and Roche can make this vision of precision medicine a reality faster than either of us could alone.". ...
Currently there is limited adoption of precision medicine programs across U.S. hospitals and the majority of organizations conducting precision medicine are focused on cancer, according to a recent study from HIMSS Analytics.. And, HIMSS Analytics survey findings indicate that most organizations cite clinical data systems integration and the integration of clinical and genomic data as a significant challenge, which underscores the need for additional electronic health record (EHR) integration and functionality.. The HIMSS Analytics 2016 Essentials Brief: Precision Medicine study provides a snapshot of how healthcare organizations are approaching the use of technology to address disease treatment and prevention that takes into account variability in genes, environment and lifestyle for each individual.. For the report, researchers surveyed 137 CMIOs/CMOs, physicians, biomedical director and pathology directors on their current approach toward precision medicine, their areas of focus, their IT ...
George and Judy Marcus Awards. Marcus Program in Precision Medicine Innovation 2019 Awardees. The Marcus Program in Precision Medicine Innovation is pleased to announce the results of the 2019 call for innovative collaborative project proposals for the Seeding Bold Ideas, Transformative Integrated Research Initiatives and ELSI in Precision Medicine (ethical, legal, social implications). We received a total of 42 excellent and potentially transformative trans-disciplinary research proposals from faculty across UCSF. 20 cross-disciplinary teams submitted proposals to the Seeding Bold Ideas (SBI) Initiative, 17 teams submitted to the Transformative Integrated Research (TIR) Initiative and 5 teams submitted to ELSI in Precision Medicine.. A committee of researchers representing basic, clinical, computational health, and social/behavioral sciences reviewed, discussed, and selected 6 SBI projects, 3 TIR projects and 1 ELSI project for funding.. ...
At the start of the year in his State of the Union Address, US President, Barrack Obama announced the launch of the Precision Medicine Initiative - a $215 million dollar plan to improve the current state of cancer diagnosis and stimulate the development of oncological therapies for specific types of the disease. This follows the reclassification of cancer as a disease of the genome; a decision made in recent years, following completion of the Human Genome Project.. Traditional cancer therapies have treated the disease on an organ-by-organ basis, categorizing the illness by the site of the primary tumor, such as the lung, breast or brain. The Precision Medicine Initiative points to a more individualized way to treat cancer based on the underlying genetic aberrations at its core.. So how will the Precision Medicine Initiative affect cancer diagnosis and patient treatment options? According to the National Cancer Institute in the US, its focusing its efforts towards personalized medicine in four ...
A rapidly developing paradigm for modern health care is a proactive and individualized response to patients symptoms, combining precision diagnosis and personalized treatment. Precision medicine is becoming an overarching medical discipline that will require a better understanding of biomarkers, phenotypes, endotypes, genotypes, regiotypes, and theratypes of diseases. The 100-year-old personalized allergen-specific management of allergic diseases has particularly contributed to early awareness in precision medicine. Polyomics, big data, and systems biology have demonstrated a profound complexity and dynamic variability in allergic disease between individuals, as well as between regions. Escalating health care costs together with questionable efficacy of the current management of allergic diseases facilitated the emergence of the endotype-driven approach. We describe here a precision medicine approach that stratifies patients based on disease mechanisms to optimize management of allergic ...
NCIs activities related to precision medicine focuses on new and expanded precision medicine clinical trials; mechanisms to overcome drug resistance to cancer treatments; and developing a shared digital repository of precision medicine trials data.
The official blog of the Annual Personalized and Precision Medicine Conference provides readers with information, insight and analysis regarding the field of personalized and precision medicine, genomics, genomic interpretation and the evolution of healthcare in the post-genomic era.
Precision Medicine Day Two - Addressing challenges to make precision medicine a reality-developing diagnostic testing, commercialising biomarkers and healthcare uptake.
Precision medicine is an upcoming disease treatment approach which is devised based on individual variability in genes, environment, and lifestyle for each person. Often the term is used interchangeably with personalized medicine, however, precision medicine is not the same as simple individualized medicine, but rather a medicine mode which combines standardization with individualization. The benefit…
Precision Medicine has the potential to improve clinical outcomes and minimize risk and adverse effects of treatments and medication. During President Obamas State of the Union address in 2015, he highlighted the promise of precision medicine and announced the Precision Medicine Initiative (PMI). Part of the PMI is the creation of the Precision Medicine Initiative Cohort. This program aims to recruit at least one million Americans to contribute their data over the span of many years to improve health outcomes, understand the impact of new treatments, and accelerate a new era of data-drive and precise preventive care and treatment. Precision medicine could address multiple issues we face, including cancer treatment and address health disparities in health disparity populations. However, little is known about health disparities populations knowledge level of precision medicine. A pilot study was conducted to investigate whether self-identified Blacks/African-Americans could define the following ...
Q: What is precision medicine?A: It is great news that improvements in the treatment for ALL (acute lymphocytic leukemia) have increased the five-year (or longer) survival rate for children (birth to 19 years old) from 80 percent in 1990 to over 90 percent now. But what is different about the 10 percent that still do not respond to these treatments? Is their disease different? Are they different?Per the National Institutes of Health, precision medicine (also called personalized medicine) is
Q: What is precision medicine?A: It is great news that improvements in the treatment for ALL (acute lymphocytic leukemia) have increased the five-year (or longer) survival rate for children (birth to 19 years old) from 80 percent in 1990 to over 90 percent now. But what is different about the 10 percent that still do not respond to these treatments? Is their disease different? Are they different?Per the National Institutes of Health, precision medicine (also called personalized medicine) is
The aetiology, clinical presentation and consequences of many high-burden diseases is heterogeneous, with current therapies failing many patients. Recent advances in biomarker technologies offer unprecedented opportunities for the stratification of these diseases into subclasses, which may yield more effective solutions for prevention, treatment and cure. Cohorts and scientists from the Nordic countries have been at the forefront of the major discoveries made in the genomics of common diseases for more than a decade. Harnessing this Nordic power-hub and exploiting its full potential requires the unification of resources, infrastructures and expertise. To this end, the Nordic Task-Force for Precision Medicine was formed in 2016. On December 4th 2017, the Task-Force will host its fourth one day symposium in Malmö, Sweden, where the major stakeholders and thought leaders will gather to overview and discuss the future of precision medicine in the Nordic region. Lectures from leading scientists and policy
To meet the challenges of increasing antimicrobial resistance, the infectious disease community needs innovative therapeutics. Precision medicine and immunotherapy are transforming cancer therapeutics by targeting the regulatory signaling pathways that are involved not only in malignancies, but also in the metabolic and immunologic function of the tumor microenvironment. Infectious diseases target many of the same regulatory pathways as they modulate host metabolic functions for their own nutritional requirements, and impede host immunity. These similarities and the advances made in precision medicine and immuno-oncology that are relevant for the current development of host-directed therapeutics (HDTs) to treat infectious diseases are discussed. To harness this potential, improvements in drug screening methods and development of assays that utilize the research tools including high through-put multiplexes already developed by oncology are essential. A multi-disciplinary approach that brings together
The study represented a segue into precision medicine for humans, said senior author Professor David James, Leonard P. Ullmann Chair of Metabolic Systems Biology at the Charles Perkins Centre.. Precision medicine classifies individuals according to their susceptibility or response to a particular disease, and tailors healthcare treatments and practices accordingly.. "Once we can identify the molecules and other factors that contribute to pre-diabetes, we can customise treatments to suit patients specific make up and needs," Professor James said.. "This study demonstrates the power of combining technologies to solve some of the worlds biggest problems," he added.. "The burden of the lifestyle diseases the Charles Perkins Centre is dedicated to easing - which include obesity, diabetes and cardiovascular disease - stubbornly remain at high levels globally; we need to innovate in order to tackle these conditions effectively." ...
Syapse, a leading precision medicine company, and Roche have joined forces to advance precision medicine in oncology. They will work together to bring real-world data to providers, bring oncology into the value-based care era, advance patient-reported outcomes, and optimize clinical trial recruiment.
In his 2015 State of the Union address, President Obama announced the Precision Medicine Initiative, a far-reaching research effort to develop medical treatments tailored for an individuals unique genetic makeup, environment and lifestyle. Instead of relying on one-size-fits-all solutions designed to help the largest number of statistically average people, such treatments could leverage advances in genetic testing, molecular engineering and big data analysis to target diseases that are often unique to each patient.. On Feb. 25, the White House held the Precision Medicine Initiative Summit, marking the anniversary of Obamas announcement. The event featured National Institutes of Health Director Francis Collins and a roundtable discussion with the President reflecting on the administrations progress in the first year of the initiative.. The White House also announced dozens of new research projects and partnerships coordinated by the NIH and the Office of Science Technology Policy. One of those ...
In such context, "World Precision Medicine (China) Summit 2016", co-organized by Sino-American Pharmaceutical Professionals Association (SAPA), Shanghai Fenglin life Healthcare Development Co., Ltd. and Healife Group will be held on December 3-4, 2016 in Shanghai, China. Under the theme of "Gaining a Clearer Perspective into Innovation Trends, Technology Advancements and Cooperation Opportunities ", WPMCS2016 brings together 1,000+ senior executives from Government, academy, hospitals, big pharmas, life sciences & biotech companies, CROs, VCPEs to discuss the redhot topics such as China-US precision medicine market outlook and evolving regulatory landscape , big data, advanced technologies and investment opportunities, biobank & cohort study, cell immunotherapy, genetic testing &IVD, innovation & cooperation of antibody drugs, clinical therapy of tumor. Geographically, besides the delegates from Mainland China, a large number will be travelling from the United States, Europe, Israel, Japan, ...
(EMAILWIRE.COM, July 08, 2020 ) Factors such as the rising government funding in precision medicine initiatives, partnerships among pharmaceutical and software companies, the entry of new players & VC funding, and growth in the number of cancer patients are driving the growth of the precision medicine...
LabRoots and the Precision Medicine Planning Committee are pleased to announce the 5th Annual Precision Medicine Virtual Event on June 17, 2020. The event will continue the dialogue
Challenge Question #4: This is the year that "big data" has arrived as a major driver of all things healthcare especially true for cancer. Its "omics", imaging, electronic medical records, cohort studies, etc., and all of these data seek to more fundamentally understand and/or create new more effective interventions for cancer We have predicted for years that with increasing data would come a new era of cancer medicine - precision medicine. Is data the fundamental foundation for precision cancer medicine? How is precision medicine advancing in oncology - or is it? Look for examples of big data informing and advancing precision medicine - give a few examples that may be transformative for patients ...
According to the National Institutes of Health (NIH), precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person." Although the text mining community has explored this realm for some years, the official endorsement and funding launched in 2015 with the Precision Medicine Initiative are beginning to bear fruit. This session sought to elicit participation of researchers with strong background in text mining and/or visualization who are actively collaborating with bench scientists and clinicians for the deployment of integrative approaches in precision medicine that could impact scientific discovery and advance the vision of precision medicine as a universal, accessible approach at the point of care ...
Theres never been a better time in the history of modern medicine to get cancer treatment, thanks to a bevy of novel therapies grouped under the name Precision medicine uses DNA testing to determine optimal drugs and is revolutionizing cancer treatment.
Targeted and personalized therapeutics are likely to transform the existing precision medicine landscape. With recent landmark regulatory approval, CAR T therapy has the potential to emerge as the industry standard for cancer management in the future and potentially replace existing treatment techniques. Bispecific and multi-specific antibody platforms are likely to emerge as the preferred alternatives for existing monotherapy strategies as they offer increased therapeutic efficacy, while reducing off-target effects. This global research service provides comprehensive insights across key technologies, research trends, funding IP outlook, clinical trials and industry innovations that are likely to transform the landscape of chimeric antigen receptor (CAR) T cell and bispecific/multi-specific T cell engaging immunotherapies.
A new study examines how one early example of precision medicine -- tumor genome testing -- is being used in women with breast cancer to reduce overtreatment and maximize the benefits of chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that physician recommendations and final treatment decisions correlated highly with test results, suggesting genome testing helped physicians identify which patients could most benefit from chemotherapy, and those for whom chemotherapy could be safely omitted.
The goal of precision medicine cancer therapies is to use drugs that target the molecular aberrations that drive cancers to improve cure rates and decrease toxicity. The Childrens Oncology Group (COG) high risk acute lymphoblastic leukemia (HR ALL) TARGET Project is a large collaborative effort led by Stephen Hunger, MD, and involving the the National Cancer Institute Office of Cancer Genomics, and investigators from Childrens Hospital of Philadelphia, Nationwide Childrens Hospital, St. Jude Childrens Research Hospital, the University of Florida, the University of New Mexico and the University of California San Francisco.. The research team has used next generation sequencing technology to study high risk ALL, leading to a large number of observations that have revolutionized understanding of the genomic landscape of ALL and identified new therapeutic targets in ALL subsets with poor treatment outcome. Based on findings from these studies, the COG AALL1131 clinical trial for children, ...
A number of recently publications have heralded the advent of Precision Medicine in Oncology, where next generation sequencing technology, other ’omics technologies, serial biopsies, so
THE UNMET NEED IN PRECISION MEDICINE. Pharma has invested heavily in genomics and "big data" to understand each patients genome to deliver targeted therapeutics, yet success rates for targeted therapies are low and uptake in clinical practice is patchy. Theres a growing realization that "just genomics" is not enough to achieve the promise of personalized therapeutics. A clear unmet need has emerged for a multi-omic approach that may offer a much greater chance of success. However, few comprehensive, multi-omic datasets exist and such data is difficult to access quickly as it is both costly and time consuming to initiate prospective data collection - especially in cancer. ...
President Barack Obama used some of his State of the Union oratory to lay out a grand vision for "precision medicine" and announce an initiative to realize it. "I want the country that eliminated polio and mapped the human genome to lead a new era of medicine-one that delivers the right treatment at the right time," he said. The initiative would help to "give all of us access to the personalized information we need to keep ourselves and our families healthier.". ...
The goal of the Journal of Laboratory and Precision Medicine is to provide a valuable platform for exchanging information in the multidisciplinary arena of precision laboratory medicine data.
Read "Ethical considerations of neuro-oncology trial design in the era of precision medicine, Journal of Neuro-Oncology" on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
In 2004, a team of Dana-Farber doctors discovered a gene mutation that could treated by a drug on the market for something else. This discovery transformed the way lung cancer is treated and began an era of precision medicine for lung cancer.
Distinguished Lecture Series in Experimental Therapeutics. In this talk, the incorporation of whole-genome, transcriptome, and proteomic testing for clinical management of patients with metastatic disease will be discussed. Also, research into genomically-informed drug combinations and novel forms of genomic variation for precision medicine will be presented. Date: 4/12/17, 9am to 10: ...
Demonstrating the potential of precision medicine, an international study based at UT Southwestern Medical Center used next-generation DNA sequencing technology to identify more than 1,000 gene variants that affect susceptibility ...
In the second study, published in Cancer Discovery, a third critical protein was identified, and a drug against this protein in combination with a TKI was able to kill the stem cells. The researchers used CML cells transplanted into mice to demonstrate that drugs targeting these proteins killed the cells that cause the leukaemia, effectively eradicating the disease. In both studies, normal blood cells were spared the effects of these novel drug combinations.. These results have potential implications for other cancers including acute myeloid leukaemia and brain tumours. The researchers are now keen to build on their work by beginning human trials in patients with drug-resistant CML. This research, although at an early stage, is a fantastic example of precision medicine in action.. In recognition of her leading-edge research, Professor Holyoake has recently been awarded a European Research Council (ERC) Advanced Grant of €3m to continue her work and has been awarded the prestigious Rowley Prize ...
Aaron Friedman is a Healthcare and Life Sciences Partner Solutions Architect at AWS. Ujjwal Ratan is a Healthcare and Life Sciences Solutions Architect at AWS. Diagnosing the medical mysteries behind acutely ill babies can be a race against time, filled with a barrage of tests and misdiagnoses. During the first few days of life, a few hours can save or seal the fate of patients admitted to the neonatal intensive care units (NICUs) and pediatric intensive care units (PICUs). Accelerating the analysis of the medical assays conducted in these hospitals can improve patient outcomes, and, in some cases, save lives.. Precision medicine relies on the aggregate of these types of tests (and others) to advance healthcare. Due to decreasing costs and faster turnaround times, genome sequencing is one such test that is gaining adoption throughout healthcare. Understanding a patients genetic predisposition to different diseases is fundamental to establishing a medical risk baseline. In certain cases, such as ...
CDC - Blogs - Genomics and Health Impact Blog - Precision Public Health and Precision Medicine: Two Peas in a Pod - Genomics and Health Impact Blog
GeneInsight, a Sunquest Company, is presenting an educational session at the Precision Medicine World Conference at Duke University , May 24-25, 2017 , in Durham, NC .
SHIVA01 and SHIVA02 are large-scale trials run in France to evaluate the efficacy of precision medicine that have created ripples in the oncology field.
New research from Healthcare IT News and HIMSS Analytics determined that precision medicine programs are rolling, albeit slowly, while early focus areas are on chronic diseases, cancer, neurology and pediatrics.
An individualized plan - based on precision medicine and tumor sequencing - shrank Jesus tumor enough that a more drastic surgery option could be avoided.
A large-scale comprehensive analysis of hepatocellular carcinoma (HCC) based on the integration of six distinct data platforms has pinpointed novel oncogenic processes and prognostic subgroups. These findings confirm previously identified molecular subclasses and fuel the need for a clear strategy of precision medicine in HCC ...
MaRS EXCITE announced today that Assurex Canada, a precision medicine company that helps patients with mental health disorders, has joined its evaluation platform.
Benjamin Shepherd - Addressing challenges to make precision medicine a reality-developing diagnostic testing, commercialising biomarkers and healthcare uptake.
|p|UC-San Franciscos new $1.5 billion hospital complex at Mission Bay opened its doors Feb. 1 with plans to use new technology and patient-centric care to pursue its mission to expand precision medicine, one of President Obamas fast-track initiatives. |/p|
A vast majority of type-2 diabetic patients (~65%) die of cardiovascular complications including heart failure (HF). In diabetic hearts, levels of 4-hydroxy-2-nonenal (4HNE), a reactive aldehyde that is produced upon lipid peroxidation, were increased. We also demonstrated that in diabetic hearts, there is a decrease in the activity of aldehyde dehydrogenase (ALDH) 2, a primary detoxifying enzyme present in cardiac mitochondria. A single point mutation at E487K of ALDH2 in East Asians known as ALDH2 * 2 intrinsically lowers ALDH2 activity. We hypothesize that Empagliflozin (EMP), a sodium-glucose cotransporter (SGLT) 2 inhibitor, can ameliorate diabetic cardiomyopathy by decreasing hyperglycemia-mediated 4HNE protein adducts in ALDH2 * 2 mutant mice which serve as a precision medicine tool as they mimic ALDH2 * 2 carriers. We induced type-2 diabetes in 11-14 month-old male and female ALDH2 * 2 mice through a high-fat diet. Chow-fed ALDH2 * 2 mice served as controls. At the end of 4 months, we treated
New York (Nextgen Seq Report) - A 20-month-old girl suffering from a rare neurodegenerative disease was diagnosed by exome sequencing and successfully treated. The case exemplifies the potential of precision medicine. Given that her disease is typically fatal, the diagnosis likely saved her life. Without advanced genetic testing, the child would most likely have been misdiagnosed […]. Continue Reading. ...
Precision medicine is slowly changing the way healthcare will work for us. But for it to take larger strides, some pitfalls need to be overcome.
Purpose of Review Despite its widespread use, oral baclofen requires a critical review of the pharmacology to determine potential precision medicine applications to improve medication administration....